Envveno Medical Corp (NVNO) Stock Price, Quote & News

Company Profile

enVVeno Medical Corporation, a medical device company, focuses on the development of bioprosthetic tissue-based solutions to enhance the standard of care in the treatment of venous disease in the United States. The company's lead product is the VenoValve, a surgical replacement venous valve for the treatment of venous chronic venous insufficiency. Its VenoValve implanted into the femoral vein of the patient in an open surgical procedure via a 5-to-6-inch incision in the upper thigh. The company...

Industry: Medical Devices

Sector: Healthcare

Phone: 949 261 2900

Website: www.envveno.com

Address:

70 Doppler, Irvine, United States

Icemanja May. 12 at 11:59 PM

$NVNO " Buy some put it away and see what we do !! " Alot of us did Berman!! And your incompetency and lies cost us millions. From the CEO who currently owns 6,350 shares , Chief Medical Officer -2,500 and the show stopper Chief Technology Officer 0 . But wait this is the only company you'll hear the CEO say is in a lock our period for the last 3 year. And that they will continue to execute. I think he mean execute another failure and total investor capital wipe out.

0 · Reply

VirtualInvestor May. 12 at 2:11 PM

$NVNO joined a #WhatThisMeans segment to discuss the FDA’s first-ever IDE approval for a U.S. pivotal study evaluating a non-surgical replacement venous valve and what this could mean for the ~3 million U.S. patients suffering from DVI. https://vimeo.com/1191510104/dade9c74de?share=copy&fl=sv&fe=ci

0 · Reply

SuperGreenToday May. 12 at 1:04 PM

$NVNO Share Price: $9.88 Contract Selected: Aug 21, 2026 $2.5 Calls Buy Zone: $0.08 – $0.09 Target Zone: $0.13 – $0.16 Potential Upside: 63% ROI Time to Expiration: 100 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

Vacuity May. 12 at 2:58 AM

$NVNO Berman trying to figure out how to squeeze every cent out of retail to line his pockets before this goes belly up

0 · Reply

cohunter9 May. 3 at 6:13 AM

$NVNO do not buy. You’ve been warned. Worse than trash. At least with trash, you can start a dumper fire.

0 · Reply

beaches911 May. 1 at 10:19 PM

$NVNO I look forward to shorting this on every pop it gets

0 · Reply

Biotech_Pharma_Investor Apr. 30 at 8:06 PM

$NVNO Trading at <$7M market cap vs $25M cash. Just got FDA approval to start their trial. PoC data from the 1st cohort should be available within cash runway.

1 · Reply

Biotech_Pharma_Investor Apr. 30 at 7:58 PM

$NVNO The first stage of the TAVVE study, which is expected to commence later this year, will consist of 10 patients, whose 30-day safety results will be submitted to the FDA for review

0 · Reply

Icemanja Apr. 29 at 9:04 PM

$NVNO The reality is , not enough vested institutional investor interest here. If they do come it will only be via a offering at deep discount to current price because of the 50 mil ATM over hang. Berman got the ATM approved because he knew no institutional investor would touch NVNO until he get full product approval if that ever happens.

0 · Reply

Icemanja Apr. 29 at 2:10 PM

$NVNO And there you have it sell the news, ATM next

0 · Reply

enVVeno Medical Discusses FDA IDE Approval in Virtual Investor "What This Means" Segment

2026-05-07T20:35:58.000Z - 5 days ago

enVVeno Medical reports Q1 EPS ($5.89) vs. ($7.75) last year

2026-05-07T20:34:39.000Z - 5 days ago

enVVeno Medical sees cash runway into 3Q27

2026-05-07T20:33:52.000Z - 5 days ago

enVVeno Medical says cash burn rate may increase to $4M-$5M per quarter

May 7, 2026, 8:05 AM EDT - 6 days ago

enVVeno Medical Reports First Quarter 2026 Financial Results and Provides Business Update Highlighting Strategic Advancement of the enVVe System

2026-04-29T14:53:15.000Z - 13 days ago

enVVeno Medical announces FDA awarded IDE approval to proceed with TAVVEB study

Apr 29, 2026, 8:05 AM EDT - 14 days ago

enVVeno Medical Receives First-Ever FDA IDE Approval for a U.S. Pivotal Study of a Non-Surgical Replacement Venous Valve

2026-03-27T12:40:21.000Z - 6 weeks ago

enVVeno Medical reports FY25 EPS ($33.06) vs. ($44.53) last year

2026-03-27T12:39:51.000Z - 6 weeks ago

enVVeno Medical expects cash burn rate of $4M-$5M per quarter in 2026

Mar 27, 2026, 8:30 AM EDT - 6 weeks ago

enVVeno Medical Reports Full Year 2025 Financial Results and Highlights Strategic Advancement of enVVe(R) System

Mar 3, 2026, 2:40 PM EST - 2 months ago

NorthStrive Fund II LP Calls on enVVeno Medical to Halt Clinical Spending Plans and Call Special Shareholder Meeting to Vote on Strategic Alternatives

2026-02-04T13:46:53.000Z - 3 months ago

enVVeno Medical regains compliance with Nasdaq minimum bid price rule

Feb 4, 2026, 8:30 AM EST - 3 months ago

enVVeno Medical Regains Compliance with Nasdaq Minimum Bid Price Requirement

2026-01-17T00:50:35.000Z - 4 months ago

enVVeno Medical trading halted, news pending

2026-01-15T13:20:22.000Z - 4 months ago

enVVeno Medical board approves 1-for-35 reverse stock split

Jan 15, 2026, 8:00 AM EST - 4 months ago

enVVeno Medical Announces Reverse Stock Split

Nov 26, 2025, 8:48 AM EST - 6 months ago

enVVeno Medical (NASDAQ:NVNO) to Participate in a Live Virtual Investor CEO Connect Segment

2025-11-13T22:30:26.000Z - 6 months ago

enVVeno Medical trading resumes

2025-11-13T22:05:19.000Z - 6 months ago

enVVeno Medical receives unfavorable FDA decision for VenoValve

Nov 13, 2025, 5:00 PM EST - 6 months ago

enVVeno Receives Unfavorable Appeal Decision from the FDA for the VenoValve

2025-11-13T21:55:16.000Z - 6 months ago

enVVeno Medical trading halted, news pending

2025-10-31T12:15:43.000Z - 6 months ago

enVVeno Medical reports Q3 EPS (23c) vs. (35c) last year

Oct 31, 2025, 8:05 AM EDT - 6 months ago

enVVeno Medical Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Sep 26, 2025, 8:45 AM EDT - 8 months ago

enVVeno Medical (NASDAQ:NVNO) Participates in Virtual Investor "What This Means" Segment

2025-09-15T12:50:06.000Z - 8 months ago

enVVeno Medical to file request for appeal of CDRH non-approvable letter

Sep 15, 2025, 8:45 AM EDT - 8 months ago

enVVeno Medical Updates Regulatory Status of VenoValve(R)

2025-08-21T01:32:00.000Z - 9 months ago

Why Is EnVVeno Medical Stock (NVNO) Down 70% Today?

2025-08-20T11:25:15.000Z - 9 months ago

enVVeno Medical receives not-approvable letter from the FDA for VenoValve

Aug 20, 2025, 7:00 AM EDT - 9 months ago

enVVeno Receives Not-Approvable Letter from the FDA for the VenoValve(R)

Aug 15, 2025, 9:21 AM EDT - 9 months ago

enVVeno Medical to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech

Aug 6, 2025, 8:30 AM EDT - 10 months ago

Health Economic Study Shows That enVVeno Medical's VenoValve(R) Would be a Cost-Effective Treatment Option for Patients with Severe Chronic Venous Insufficiency

2025-08-04T13:15:24.000Z - 10 months ago

enVVeno participates in ‘What This Means’ segment on Trump’s CVI diagnosis

Aug 4, 2025, 9:05 AM EDT - 10 months ago

enVVeno Medical Participates in a New Virtual Investor "What This Means" Segment to Discuss How President Trump's Recent CVI Diagnosis May Impact the Company

2025-08-01T12:16:38.000Z - 10 months ago

enVVeno Medical reports Q2 EPS (33c) vs. (31c) last year

Aug 1, 2025, 8:00 AM EDT - 10 months ago

enVVeno Medical Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Jul 22, 2025, 8:45 AM EDT - 10 months ago

enVVeno Medical Participates in the Virtual Investor "What's Your Story" Summer Spotlight On-Demand Conference

Jun 6, 2025, 8:05 AM EDT - 1 year ago

Positive Interim 2-Year Data from enVVeno Medical's VenoValve Pivotal Study to be Presented Today at the Society for Vascular Surgery (SVS) 2025 Vascular Annual Meeting

May 19, 2025, 8:05 AM EDT - 1 year ago

enVVeno Medical Appoints Jennifer Bright as Chief Financial Officer

May 13, 2025, 8:45 AM EDT - 1 year ago

Three-Year VenoValve(R) First-in-Human Trial Data Published in the Annals of Vascular Surgery

May 1, 2025, 8:05 AM EDT - 1 year ago

enVVeno Medical Reports First Quarter 2025 Financial Results and Reiterates Progress Toward VenoValve FDA Decision Expected in 2H24

Apr 23, 2025, 8:00 AM EDT - 1 year ago

VenoValve to be Featured During Presentation at the 47th Annual Charing Cross Symposium

Apr 16, 2025, 8:30 AM EDT - 1 year ago

enVVeno Medical to Participate in a Live Virtual Investor Closing Bell Segment

Mar 31, 2025, 9:00 AM EDT - 1 year ago

The Impact of the VenoValve(R) on Patients with Primary and Secondary Chronic Venous Insufficiency (CVI) to be Presented at the Society for Clinical Vascular Surgery 52nd Annual Symposium

Feb 28, 2025, 8:00 AM EST - 1 year ago

enVVeno Medical Reports Fourth Quarter and Year-End 2024 Financial Results and Progress Towards VenoValve FDA Approval Expected in 2H25

Feb 19, 2025, 9:00 AM EST - 1 year ago

enVVeno Medical Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

Feb 19, 2025, 8:45 AM EST - 1 year ago

One-Year Data from the VenoValve(R) U.S. Pivotal Trial Highlighting Impact on Patients' Quality of Life (QOL) to be Presented Today at the 37th Annual Meeting of the American Venous Forum

Feb 7, 2025, 9:00 AM EST - 1 year ago

Interim Two-Year Follow-Up Data from the VenoValve(R) U.S. Pivotal Trial to be Presented Today at the VESS 2025 Annual Winter Meeting

Dec 16, 2024, 8:50 AM EST - 1 year ago

enVVeno Medical Successfully Completes Final Wave of Implants in Pre-Clinical GLP Study for enVVe

Nov 27, 2024, 8:30 AM EST - 1 year ago

enVVeno Medical Highlights Successful 2024 VEITH Symposium with Launch of Recap Website

Nov 20, 2024, 8:30 AM EST - 1 year ago

enVVeno Medical to Present Definitive One Year Data from the VenoValve U.S. Pivotal Trial Today at the 51st Annual VEITH Symposium

Nov 19, 2024, 8:15 AM EST - 1 year ago

enVVeno Medical Submits the VenoValve PMA Application Seeking FDA Approval

Sep 24, 2021, 9:00 AM EDT - 5 years ago

Hancock Jaffe to Participate in the Duologue Series Virtual Webinar Hosted by Ladenburg Thalmann

Sep 21, 2021, 4:00 PM EDT - 5 years ago

Hancock Jaffe Announces Corporate Rebranding to Reflect Prioritization of its Development Pipeline on Venous Disease Programs

Sep 15, 2021, 8:05 AM EDT - 5 years ago

Hancock Jaffe to Host Corporate Update Conference Call and Webcast on September 21, 2021

Sep 7, 2021, 8:05 AM EDT - 5 years ago

Hancock Jaffe Laboratories Announces $20 Million Registered Direct Offering Priced At-the-Market Under NASDAQ Rules

Aug 19, 2021, 8:00 AM EDT - 5 years ago

Hancock Jaffe Presents New Positive Two-Year VenoValve Data at the Society for Vascular Surgery Annual Meeting

Aug 3, 2021, 8:05 AM EDT - 5 years ago

FDA Grants Breakthrough Device Designation Status for Hancock Jaffe's VenoValve

Jul 8, 2021, 9:05 AM EDT - 5 years ago

Hancock Jaffe to Present at the Ladenburg Thalmann 2021 Healthcare Conference

Apr 23, 2021, 12:40 PM EDT - 5 years ago

Hancock Jaffe Principal Investigator Dr. Jorge Hernando Ulloa Presents VenoValve One Year First-In-Human Data at Charing Cross International Symposium

Apr 7, 2021, 1:40 PM EDT - 5 years ago

First U.S. Patent Issues on Hancock Jaffe VenoValve

Apr 5, 2021, 7:30 AM EDT - 5 years ago

Hancock Jaffe Receives IDE Approval To Begin VenoValve U.S. Pivotal Trial

Mar 8, 2021, 8:30 AM EST - 5 years ago

Hancock Jaffe Submits IDE Application to FDA for VenoValve U.S. Pivotal Trial

Jan 12, 2021, 8:30 AM EST - 5 years ago

Hancock Jaffe Concludes Successful VenoValve Pre-IDE Meeting with FDA

Dec 30, 2020, 4:15 PM EST - 5 years ago

Hancock Jaffe Announces Executive Promotions

Dec 21, 2020, 8:30 AM EST - 5 years ago

Hancock Jaffe Deemed Compliant With All NASDAQ Continued Listing Requirements

Icemanja May. 12 at 11:59 PM

0 · Reply

VirtualInvestor May. 12 at 2:11 PM

0 · Reply

SuperGreenToday May. 12 at 1:04 PM

0 · Reply

Vacuity May. 12 at 2:58 AM

$NVNO Berman trying to figure out how to squeeze every cent out of retail to line his pockets before this goes belly up

0 · Reply

cohunter9 May. 3 at 6:13 AM

$NVNO do not buy. You’ve been warned. Worse than trash. At least with trash, you can start a dumper fire.

0 · Reply

beaches911 May. 1 at 10:19 PM

$NVNO I look forward to shorting this on every pop it gets

0 · Reply

Biotech_Pharma_Investor Apr. 30 at 8:06 PM

$NVNO Trading at <$7M market cap vs $25M cash. Just got FDA approval to start their trial. PoC data from the 1st cohort should be available within cash runway.

1 · Reply

Biotech_Pharma_Investor Apr. 30 at 7:58 PM

$NVNO The first stage of the TAVVE study, which is expected to commence later this year, will consist of 10 patients, whose 30-day safety results will be submitted to the FDA for review

0 · Reply

Icemanja Apr. 29 at 9:04 PM

0 · Reply

Icemanja Apr. 29 at 2:10 PM

$NVNO And there you have it sell the news, ATM next

0 · Reply

DonVigo Apr. 29 at 1:48 PM

$NVNO Will end up like TTOO and Casava. Believe me!

0 · Reply

Bulut21 Apr. 29 at 1:16 PM

$NVNO enVVeno Medical Receives First-Ever FDA IDE Approval for a U.S. Pivotal Study of a Non-Surgical Replacement Venous Valve $SAGT $INHD $XTLB $AIXI

0 · Reply

Gbang77 Apr. 29 at 1:09 PM

$NVNO News out. Nano float. NFA

0 · Reply

Bulut21 Apr. 29 at 12:38 PM

$NVNO https://finance.yahoo.com/sectors/healthcare/articles/envveno-medical-receives-first-ever-120500979.html $INHD $SAGT $GCTK $RDAC

0 · Reply

Neegud Apr. 29 at 12:13 PM

$NVNO added on FDA news. Super low float.

0 · Reply

PLEBTRADER Apr. 29 at 12:08 PM

$NVNO here we go again

0 · Reply

Rco002 Apr. 22 at 10:56 PM

$NVNO lost my kids college fund with this. Now I’m turning tricks and jacking off punks underneath the Brooklyn bridge for $5 a pop. Thanks Berman.

0 · Reply

Biotech_Pharma_Investor Apr. 22 at 4:07 PM

$NVNO A spike here is long overdue

0 · Reply

cohunter9 Apr. 19 at 4:12 AM

$NVNO I limited losses with options. They have nothing, do not lose money here

0 · Reply

OfficialStocktwitsUser Apr. 18 at 2:07 AM

$NVNO RSI: 71.94, MACD: 0.1279 Vol: 0.46, MA20: 10.82, MA50: 10.71 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

AtlasAnalysis Apr. 16 at 2:46 PM

$NVNO 100% feasible just need high volume

0 · Reply

BigGreenCandle Apr. 14 at 11:13 PM

$NVNO This POS never had any kind of move and now that it has a vapor thin float I'd love to see some stupid pump to $40. C'mon, Berman. Do something interesting for once.

0 · Reply

Market Cap	6.60M
Revenue (ttm)	0.00
Net Income (ttm)	-19.47M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	16,700
Avg Vol	13,468
Day's Range	N/A - N/A
Shares Out	668,000.00
Stochastic %K	13%
Beta	1.08
Analysts	Hold
Price Target	$12.50